NCT07130383View on ClinicalTrials.gov

A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2031

Conditions
Advanced Breast CancerAdvanced Malignant Solid Tumor
Interventions
DRUG

MHB036C for Injection

Intravenous administration

DRUG

MHB039A for Injection

Intravenous administration

Sponsors
All Listed Sponsors
lead

Minghui Pharmaceutical (Hangzhou) Ltd

INDUSTRY